BridgeBio's Infigratinib Shows Broad Benefits in Dwarfism Trial, FDA Filing Submitted
BBIO sits 53% above its 52-week low of $48.78 on light trading volume (0.1× avg).
Summary
BridgeBio released 52-week data from the PROPEL 3 trial of oral infigratinib in achondroplasia, showing benefits beyond height gain. Sleep apnea worsened far less with the drug (10.4% AHI increase vs 49.2% placebo), and ear infections were 38% lower. The company has submitted an FDA application and expects a U.S. launch in mid-2027, with an EMA filing planned for Q4 2026. This is the first detailed look at these secondary endpoints and confirms the regulatory path for what could be the first approved oral therapy for this condition. The stock barely moved premarket, suggesting the data was largely in line with expectations, but the breadth of benefit strengthens the commercial case.
At the time of this announcement, BBIO was trading at $74.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.6B. The 52-week trading range was $48.78 to $93.42. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.